Xeris Biopharma (XERS) Competitors $5.02 -0.15 (-2.90%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$5.00 -0.01 (-0.30%) As of 07/25/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XERS vs. HCM, IMVT, KYMR, CRNX, MOR, ALVO, MIRM, CPRX, GMTX, and AMRXShould you be buying Xeris Biopharma stock or one of its competitors? The main competitors of Xeris Biopharma include HUTCHMED (HCM), Immunovant (IMVT), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), MorphoSys (MOR), Alvotech (ALVO), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), Gemini Therapeutics (GMTX), and AMNEAL PHARMACEUTICALS (AMRX). These companies are all part of the "pharmaceutical products" industry. Xeris Biopharma vs. Its Competitors HUTCHMED Immunovant Kymera Therapeutics Crinetics Pharmaceuticals MorphoSys Alvotech Mirum Pharmaceuticals Catalyst Pharmaceuticals Gemini Therapeutics AMNEAL PHARMACEUTICALS HUTCHMED (NASDAQ:HCM) and Xeris Biopharma (NASDAQ:XERS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership. Do analysts prefer HCM or XERS? HUTCHMED currently has a consensus target price of $23.50, indicating a potential upside of 33.45%. Xeris Biopharma has a consensus target price of $6.25, indicating a potential upside of 24.50%. Given HUTCHMED's higher probable upside, research analysts clearly believe HUTCHMED is more favorable than Xeris Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HUTCHMED 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Xeris Biopharma 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has better earnings & valuation, HCM or XERS? HUTCHMED has higher revenue and earnings than Xeris Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHUTCHMED$630.20M4.87$37.73MN/AN/AXeris Biopharma$203.07M3.87-$54.84M-$0.30-16.73 Does the media prefer HCM or XERS? In the previous week, HUTCHMED had 1 more articles in the media than Xeris Biopharma. MarketBeat recorded 5 mentions for HUTCHMED and 4 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.28 beat HUTCHMED's score of 1.02 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in HCM or XERS? 8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by company insiders. Comparatively, 6.5% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, HCM or XERS? HUTCHMED has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Is HCM or XERS more profitable? HUTCHMED has a net margin of 0.00% compared to Xeris Biopharma's net margin of -20.25%. Company Net Margins Return on Equity Return on Assets HUTCHMEDN/A N/A N/A Xeris Biopharma -20.25%N/A -12.07% SummaryHUTCHMED beats Xeris Biopharma on 7 of the 13 factors compared between the two stocks. Get Xeris Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XERS vs. The Competition Export to ExcelMetricXeris BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$785.05M$2.49B$5.70B$9.50BDividend YieldN/A1.65%4.58%4.00%P/E RatioN/A9.1828.3920.07Price / Sales3.87617.35427.4498.54Price / CashN/A165.2136.2258.56Price / Book-25.105.168.675.88Net Income-$54.84M$30.99M$3.25B$258.89M7 Day Performance-1.76%7.73%4.30%3.70%1 Month Performance5.91%16.27%10.57%11.71%1 Year Performance92.34%-1.88%35.68%17.98% Xeris Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XERSXeris Biopharma4.0021 of 5 stars$5.02-2.9%$6.25+24.5%+96.5%$785.05M$203.07M0.00290News CoveragePositive NewsHCMHUTCHMED2.7403 of 5 stars$17.74+0.9%$19.00+7.1%-2.2%$3.07B$630.20M0.001,811News CoveragePositive NewsAnalyst ForecastIMVTImmunovant1.267 of 5 stars$17.70-1.2%$36.30+105.1%-39.0%$3.06BN/A-6.46120News CoverageGap DownKYMRKymera Therapeutics3.1588 of 5 stars$45.14-2.3%$59.11+31.0%+4.0%$3.01B$47.07M-14.56170Positive NewsCRNXCrinetics Pharmaceuticals3.673 of 5 stars$30.95-0.5%$69.50+124.6%-41.9%$2.91B$1.04M-8.10210Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730ALVOAlvotech2.6983 of 5 stars$8.64+0.1%$16.00+85.2%-14.9%$2.60B$491.98M23.351,032MIRMMirum Pharmaceuticals3.8501 of 5 stars$51.95+0.0%$65.50+26.1%+28.4%$2.57B$336.89M-32.27140Positive NewsCPRXCatalyst Pharmaceuticals4.9207 of 5 stars$21.01-0.1%$32.83+56.3%+20.7%$2.57B$491.73M13.3880News CoveragePositive NewsAnalyst RevisionGMTXGemini TherapeuticsN/A$57.770.0%N/A+36.0%$2.50BN/A-57.7730High Trading VolumeAMRXAMNEAL PHARMACEUTICALS3.1309 of 5 stars$7.91-0.8%$11.60+46.6%+9.2%$2.50B$2.79B-197.708,100 Related Companies and Tools Related Companies HCM Alternatives IMVT Alternatives KYMR Alternatives CRNX Alternatives MOR Alternatives ALVO Alternatives MIRM Alternatives CPRX Alternatives GMTX Alternatives AMRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XERS) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
